| Literature DB >> 33817413 |
Susan Y Wu1, Emily Yee2, Jason W Chan2, Christopher H Chapman2, Lauren Boreta2, Steve E Braunstein2.
Abstract
PURPOSE: Urgent indications for palliative radiation therapy (RT) include malignant spinal cord compression, symptomatic brain metastases, pain, airway obstruction, and bleeding. Data on the timing of palliative RT in the inpatient setting are limited. We report our experience with inpatient palliative RT at a tertiary academic center and evaluate the effect of a dedicated inpatient palliative RT nurse practitioner (NP) on treatment timelines. METHODS AND MATERIALS: We performed a retrospective, single-institution review of 219 inpatients consulted for RT to sites of metastatic disease between May 2012 and May 2018. We compared time-to-treatment intervals before and after integrating an NP for palliative RT in August 2017.Entities:
Year: 2021 PMID: 33817413 PMCID: PMC8005735 DOI: 10.1016/j.adro.2021.100670
Source DB: PubMed Journal: Adv Radiat Oncol ISSN: 2452-1094
Patient characteristics
| Characteristic | Median (IQR) or No. (%) | Before NP | With NP | |
|---|---|---|---|---|
| Age, y | ||||
| At diagnosis | 59 (48-67) | 58 (46-67) | 61 (52-66) | .22 |
| At palliative radiation therapy | 61 (51-69) | 60 (51-69) | 64 (55-68) | .25 |
| Sex | .41 | |||
| Male | 93/219 (43) | 67/164 (41) | 26/55 (47) | |
| Female | 126/219 (58) | 97/164 (59) | 29/55 (53) | |
| KPS | 60 (40-70) | 50 (40-60) | 70 (60-80) | |
| Race | ||||
| White | 131/219 (60) | 108/164 (66) | 23/55 (42) | |
| Black | 25/219 (11) | 20/164 (12) | 5/55 (9) | |
| Asian | 48/219 (22) | 33/164 (20) | 15/55 (27) | |
| Other/declined | 15/219 (7) | 3/164 (2) | 12/55 (22) | |
| Primary histology | ||||
| Lung | 55/219 (25) | 46/164 (10) | 9/55 (16) | |
| Breast | 28/219 (13) | 22/164 (13) | 6/55 (11) | |
| Myeloma | 26/219 (12) | 9/164 (5) | 17/55 (31) | |
| Liver | 14/219 (6) | 11/164 (7) | 3/55 (6) | |
| Head and neck | 12/219 (6) | 10/164 (6) | 2/55 (4) | |
| Colorectal | 10/219 (5) | 10/164 (6) | 0/55 (0.0) | |
| Skin | 8/219 (4) | 7/164 (4) | 1/55 (2) | |
| Renal | 8/219 (4) | 8/164 (5) | 0/55 (0) | |
| Bladder/urothelium | 7/219 (3) | 35/164 (3) | 2/55 (5) | |
| Endometrium | 6/219 (3) | 5/164 (3) | 1/55 (2) | |
| Melanoma | 5/219 (2) | 4/164 (2) | 1/55 (2) | |
| Other | 40/219 (18) | 27/164 (16) | 13/55 (24) | |
| Treatment indications | ||||
| Symptomatic brain metastasis/LMD | 73/219 (33) | 65/164 (40) | 8/55 (15) | |
| Cord/cauda compromise | 48/219 (22) | 37/164 (23) | 11/55 (20) | |
| Cranial neuropathy owing to skull base metastases | 11/219 (5.0) | 5/164 (3) | 6/55 (11) | |
| Other neurological indications | 4/219 (1.8) | 1/164 (1) | 3/55 (6) | |
| Pain | 61/219 (28) | 45/164 (27) | 16/55 (29) | |
| Bleeding | 8/219 (3.6) | 3/164 (2) | 5/55 (9) | |
| Other | 10/219 (4.6) | 5/164 (3) | 5/55 (9) | |
| Asymptomatic bone metastases | 4/219 (1.8) | 3/164 (2) | 1/55 (2) | |
| Treatment site | ||||
| Bone | 52) (113/219) | 51) (84/164) | 53) (29/55) | |
| Brain | 34) (74/219) | 40) (65/164) | 16) (9/55) | |
| Intrathoracic | 4.1) (9/219) | 3.0) (5/164) | 7.5) (4/55) | |
| Lymph nodes | 3.2) (7/219) | 1.2) (2/164) | 9.1) (5/55) | |
| Other | 7.3) (16/219) | 4.9) (8/164) | 15) (8/55) | |
| Prescribed fractions | 6 (3-13) | 6 (3-13) | 6 (3-11) | .21 |
| Fractions received | 5 (5-10) | 5 (5-10) | 5 (4-10) | .28 |
| RT modality | .45 | |||
| 2D/3D | 84) (183/219) | 84) (138/164) | 80) (44/55) | |
| IMRT | 15) (32/219) | 14) (23/164) | 20) (9/55) | |
| SBRT | 1.8) (4/219) | 1.2) (2/164) | 3.6) (2/55) |
Abbreviations: IMRT = intensity modulated radiation therapy; IQR = interquartile range; KPS = Karnofsky Performance Score; LMD = leptomeningeal disease; NP = nurse practitioner; RT = radiation therapy; SBRT = stereotactic body radiation therapy.
Bold P values indicate statistically significant.
Includes pancreas, ovary, primary central nervous system, thyroid, esophageal, stomach, mesothelioma, lymphoma, soft tissue sarcoma, and unknown primary.
Seen in 15 of 67 patients.
Includes brachial plexopathy and neurologic symptoms from calvarial metastasis.
Includes superior vena cava syndrome and airway obstruction.
Includes visceral and cutaneous lesions.
Time between radiation therapy (RT) components
| RT indication | Days from consultation request to consult (IQR) | Days from consultation to simulation (IQR) | Days from simulation to RT (IQR) | Days from consultation request to RT (IQR) |
|---|---|---|---|---|
| Cord/cauda compression | 1 (0-2) | 0 (0-0) | 0 (0-1) | 2 (1-4) |
| Symptomatic brain metastases | 1 (0-2) | 0 (0-1) | 1 (0-3) | 3 (1-6) |
| Cranial neuropathy owing to skull base metastases | 1 (0-1) | 0 (0-1) | 3 (1-4) | 3 (2-6) |
| Pain | 1 (1-2) | 0 (0-2) | 2 (1-4) | 5 (2-7) |
| Bleeding | 2 (0-3) | 0 (0-2) | 1 (0-2) | 3 (2-7) |
| Airway obstruction | 2 (1-2) | 2 (1-2) | 5 (5-5) | 9 (7-9) |
Abbreviation: IQR = interquartile range.
Multivariable regression analysis
| Model component | Referral to consult (B, 95% CI) | Referral to simulation (B, 95% CI) | Consult to RT (B, 95% CI) | Simulation to RT (B, 95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| Age at diagnosis | –0.03 (–1.94 to 2.60) | .58 | –0.03 (–0.15 to 0.09) | .62 | –0.01 (–0.12 to 0.10) | .85 | 0.013 (–0.07 to 0.09) | .74 |
| Age at RT | 0.04 (–0.12 to 0.07) | .43 | 0.06 (–0.07 to 0.19) | .37 | 0.04 (–0.08 to 0.16) | .47 | –0.001 (–0.09 to 0.09) | .99 |
| Gender | 0.56 (–0.29 to 1.41) | .19 | 0.23 (–0.89 to 1.36) | .68 | –0.47 (–1.74 to 0.80) | .68 | 0.24 (–0.69 to 1.17) | .61 |
| KPS | 0.01 (–0.02 to 0.02) | 1.00 | 0.002 (–0.03 to 0.04) | .88 | 0.01 (–0.03 to 0.05) | .88 | 0.01 (–0.02 to 0.04) | .40 |
| Indication | 0.19 (–0.07 to 0.45) | .15 | 0.34 (–0.005 to 0.68) | 0.34 (–0.01 to 0.68) | 0.44 (0.14 to 0.74) |
Abbreviations: KPS = Karnofsky Performance Score; RT = radiation therapy.
Bold P values indicate statistical significance.